Video

Our team behind the scenes at SXSW | Building a Disease Specific Knowledge Base

In part two of our SXSW series, our team shows how we use AI and machine learning to better understand specific diseases - in this case, Glioblastoma (GBM), the most common and aggressive form of brain cancer.

Given the complexity of a savage disease like GBM, a scientist alone could not read up on all the research that has been done to understand it. At BenevolentAI, we have developed a biomedical knowledge base to contextualise all the relevant information and relationships between diseases, genes, drugs and other important research that has already been published.

Our knowledge graph pulls out all the relevant links to ongoing and completed clinical trials, existing compounds that have been tested against the disease, and the underlying biological connections known to be associated with the disease. Together, these biological facts represent all that is known to be true about a disease today.

Our technology platform helps us understand diseases like GBM by sitting on top of this knowledge base and answering two fundamental questions, i) what do we know about the disease today? and ii) where are the gaps in that knowledge base?


Watch our team demonstrate how algorithms can analyse this knowledge and reason across it to provide scientists and researchers with capabilities beyond human insight.

More Posts

You Might Also Like

Blog
Transforming drug discovery with AI: how we’re building and nurturing the best talent for the job
At BenevolentAI, we are on a mission to bring life-changing medicines to patients, and we are looking for collaborative, mission-driven people to join our tech, drug discovery and business operations teams in London, Cambridge and New York.
Oct 17, 2021
News
BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies
BenevolentAI’s AI-Drug Discovery platform uncovered a novel target not previously linked to ulcerative colitis and advanced candidate to preclinical studies.
Oct 14, 2021
Blog
Measuring bias: moving towards more inclusive health research outcomes #stateofai
Having shared our open-source Diversity Analysis Tool last year, we were tasked to investigate and demonstrate the lack of diversity in biomedical data as part of the State of AI Report 2021.
Oct 12, 2021
Blog
Expert-augmented computational drug discovery for rare diseases
Combining scientific expertise, computational tools and our AI-enhanced biomedical knowledge graph to successfully uncover a new drug combination for treating a rare brain cancer in children.
Sep 28, 2021
News
BenevolentAI appoints Dr John Orloff to its Board of Directors
Biopharmaceutical veteran Dr John Orloff joins the BenevolentAI Board as a Non-Executive Director as it scales the development of its leading AI-derived drug pipeline.
Sep 9, 2021
Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021